An Unsurprising Pipeline Failure

Eli Lilly (NYSE: LLY  ) announced yesterday that it would be ending its rheumatoid arthritis program for its drug tabalumab. In December, Lilly ended one of its three trials for this drug because it was showing no benefit, and it's now ended the other two trials for similar reasons. In the video, Brenton tells us about the drug's other potential application in the lupus space, and some other pipeline candidates it will be falling back on as it tries to gain share in the lucrative arthritis market.

The patent cliff cometh
Over the next two years, Eli Lilly will see nearly $0.40 of every $1.00 in sales exposed to generic competition. How does the company plan to respond to this huge patent cliff? Better yet, what does this mean for investors? In a brand new premium report on Eli Lilly, The Motley Fool's top pharmaceuticals analyst delves into everything investors need to know about the stock today. Simply click here now to claim your copy.


Read/Post Comments (1) | Recommend This Article (2)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On February 09, 2013, at 11:11 AM, HungryHunter12 wrote:

    I agree with the risk of banks dominating ETFs in developing markets. How does one find the consumer, health care and other attractive companies in those markets?

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2244719, ~/Articles/ArticleHandler.aspx, 10/26/2014 3:51:56 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Apple's next smart device (warning, it may shock you

Apple recently recruited a secret-development "dream team" to guarantee its newest smart device was kept hidden from the public for as long as possible. But the secret is out. In fact, ABI Research predicts 485 million of this type of device will be sold per year. But one small company makes Apple's gadget possible. And its stock price has nearly unlimited room to run for early-in-the-know investors. To be one of them, and see Apple's newest smart gizmo, just click here!


Advertisement